Helping immunotherapy realize its full potential to treat cancer - through the gut microbiome.
MISSION
To develop therapies that modulate the gut microbiome to improve the outcomes and quality of life of patients with cancer.
Sidekick Bio is a biopharmaceutical company developing innovative therapies that alter the gut microbiome in order to improve the safety and efficacy of cancer immunotherapy and enable more patients to achieve a durable response. Sidekick Bio is committed to advancing the field of microbiome-based medicine and improving outcomes for patients with cancer.
FOUNDING TEAM
Sidekick Bio was founded by a team of experienced biopharma executives with deep expertise in the microbiome, oncology, and clinical development, passionate about advancing our science into transformative medicines.
-
Raul Oliva
-
David Brooks, MD, PhD
-
Kim Hocknell
-
Elisa Asanza
-
Johan van Hylckama Vlieg, PhD
-
Ulrich Binné, PhD, JD
-
Alison Lawton
-
Michael W. Bonney